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Polo-like kinase 1 (PLK1) and BRD4 are two different therapeutic targets in cancer drug 
discovery. Recently it has been reported that PLK1 inhibitor, BI-2536, is also a potent inhibitor 
of BRD4. The simultaneous inhibition of PLK1 and BRD4 by a single drug molecule is 
interesting because this could lead to the development of effective therapeutic strategy for 
different types of disease conditions in which PLK1 and BRD4 are implicated. Structural activity 
relationship studies has been carried out on BI-2536 to generate analogs with enhanced dual 
inhibitory activity against BRD4 and PLK1 as well as to render the molecule selective to one 
target over the other. UMB101 and 160 have been found to exhibit enhanced dual inhibitory 
activity with selectivity fold of less than 30, UMB160 being the most potent dual-kinase 
bromodomain inhibitor (BRD4 IC50 = 28 nM, PLK1 IC50 = 40 nM). UMB131 was found to be the 
most selective PLK1 inhibitor over BRD4. 
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